Equillium, Inc. (EQ)
- Previous Close
1.7900 - Open
1.7900 - Bid 1.7400 x 100
- Ask 1.8600 x 100
- Day's Range
1.6700 - 1.8500 - 52 Week Range
0.4500 - 3.2500 - Volume
130,363 - Avg. Volume
371,630 - Market Cap (intraday)
63.811M - Beta (5Y Monthly) 1.67
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3800 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
www.equilliumbio.comRecent News: EQ
Performance Overview: EQ
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EQ
Valuation Measures
Market Cap
63.81M
Enterprise Value
23.77M
Trailing P/E
--
Forward P/E
3.29
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.74
Price/Book (mrq)
2.83
Enterprise Value/Revenue
0.66
Enterprise Value/EBITDA
-1.96
Financial Highlights
Profitability and Income Statement
Profit Margin
-36.96%
Return on Assets (ttm)
-14.08%
Return on Equity (ttm)
-48.92%
Revenue (ttm)
36.08M
Net Income Avi to Common (ttm)
-13.34M
Diluted EPS (ttm)
-0.3800
Balance Sheet and Cash Flow
Total Cash (mrq)
40.87M
Total Debt/Equity (mrq)
3.65%
Levered Free Cash Flow (ttm)
-6.68M